Navigation Links
Warner Chilcott Successfully Completes Refinancing of Senior Secured Credit Facilities and Updates Full Year 2011 Financial Guidance
Date:3/17/2011

DUBLIN, March 17, 2011 /PRNewswire/ -- Warner Chilcott plc (Nasdaq: WCRX) announced today that certain of its subsidiaries have successfully completed the refinancing of the Company's prior senior secured credit facilities.  The Company used the proceeds of its term loan borrowings under its new senior secured credit facilities, as well as approximately $279 million of cash on hand, to repay and terminate its prior senior secured credit facilities and to pay related fees and expenses.  The Company's new $3.25 billion senior secured credit facilities are comprised of a $1.25 billion Term Loan A facility maturing in 2016 and bearing interest at LIBOR plus 3.00% (with a LIBOR floor of 0.75%), a $1.75 billion Term Loan B facility maturing in 2018 and bearing interest at LIBOR plus 3.25% (with a LIBOR floor of 1.00%) and a $250 million revolving credit facility maturing in 2016 which remained undrawn at the closing.  

Financial GuidanceThe Company is also affirming its previously issued full year 2011 financial guidance ranges for total revenue, gross margin, SG&A expense, R&D expense and income taxes, while updating its projections for GAAP net income, cash net income ("CNI") and CNI per share as a result of successfully completing the debt refinancing. CNI is defined as the Company's GAAP net income adjusted for the after-tax effects of two non-cash items: amortization (including impairments, if any) of intangible assets and amortization (including write-offs, if any) of deferred loan costs related to its debt.

The Company now estimates that its full year 2011 GAAP net income will decrease by approximately $15 million and be in the range of $255 million to $281 million, primarily driven by the write-down of previously outstanding deferred loan costs in connection with the refinancing which are expected to more than offset reduced cash interest
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive
2. Warner Chilcott Announces 2011 Financial Guidance Conference Call
3. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
4. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
5. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
6. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
7. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
8. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
9. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
10. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
11. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 , ... part) in, into or from any jurisdiction where to do ... such jurisdiction.  Shire plc ("Shire" or the "Company") ... article this afternoon.  Shire confirms it has held a meeting ... made by Shire without the prior agreement or approval of ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
(Date:7/10/2014)... July 10, 2014 Unraveling life’s mysteries ... The Archer Family purchased a DNA test ... but ended up with a lifetime of memories, sharing, ... the family members’ DNA genuinely brought the family closer ... search deeper into genetic history and prior to taking ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... YORK, Oct. 23 Keryx Biopharmaceuticals,Inc. (Nasdaq: ... notice from The,Nasdaq Stock Market ("Nasdaq") stating that ... a minimum bid price of,$1.00 per share, has ... the Company that it now has until January ...
... Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... abstract entitled "Phase I Trial,of Oncolytic Reovirus ... Advanced Solid Cancers" will be,available in the ... official journal of the International Society for ...
... Md., Oct. 23 MedImmune today announced,that researchers ... at the Annual Meeting of the American College ... the Moscone Center in San Francisco, California., ... solutions for patients,struggling with systemic autoimmune rheumatic diseases," ...
Cached Biology Technology:Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 3MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology 2MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology 3
(Date:7/11/2014)... burning in eastern New South Wales, Australia when NASA,s ... 03:35 UTC on July 11 (12:35 p.m. local time/11:35 ... eastern New South Wales (NSW), the Moderate Resolution Imaging ... the region and spotted smoke (light brown) from various ... are outlined in red. , The New South Wales, ...
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... Salk Institute for Biological Studies, BGI, and other ... and reliability of the existing targeted gene correction ... which could significantly increased gene-correction efficiency in human ... online in Cell Stell Cell provides ... therapy. , The combination of stem cells and ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... and monkeys don,t develop diseases in the same way that ... in a Petri dish, they have little choice but to ... of Washington bioengineers have developed the first structure to grow ... offers a better way to study disease, test drugs and ...
... It took some 10 million years for Earth to recover ... has revealed., Life was nearly wiped out 250 million years ... surviving. It is currently much debated how life recovered from ... rapid bounce-back is evaluated in a new review article by ...
... of red blood cells (RBC) is a critical ... acute and chronic medical problems. Indeed, approximately 75 ... are annually collected worldwide for processing and eventual ... for blood constantly exceeds availability due to a ...
Cached Biology News:Engineered microvessels provide a 3-D test bed for human diseases 210 million years to recover from mass extinction 2Proteomic analysis of immunocamouflaged surfaces 2
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: reusable ...
... LS Low Speed Shaker ,Product ... speed shaker is a high quality, general purpose ... ,Styled after the other models in the line, ... with easy-access control panel. Electronic controls are utilized ...
... CromoCenSC is a chromogenic medium for ... of Salmonella (except S. thyphi) and ... ,The detection takes a maximum of ... tests, no sterilization during preparation and ...
... leading provider of X-ray crystallography services ... screening services to its pharmaceutical and ... binding of drug-like fragments to the ... targets, allowing scientists to develop novel, ...
Biology Products: